EMERALD-2: This is a study to assess the safety and efficacy of Durvalumab alone or in combination with Bevacizumab (Avastin) in Hepatocellular Carcinoma (HCC) patients at high risk of recurrence after curative treatment. For more information, click here or phone (08) 9242 7640. You can register your interest in this study by filling out this form.